Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small cell lung cancer (ICTAN, GASTO1002): a randomized phase 3 trial
Rezivertinib versus Gefitinib as First-line Therapy for EGFR-mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-blinded, Randomized Phase 3 Study
SOX4-BMI1 Axis Promotes Non-Small Cell Lung Cancer Progression and Facilitates Angiogenesis by Suppressing ZNF24
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
Alkaloids of Aconiti Lateralis Radix Praeparata treated non-small cell lung cancer by regulating glycolysis via the PI3K/AKT-mTOR signaling pathway
Synergistic effects of cannabidiol and cytokine-induced killer cells via the modulation of TRPV2 channel and intracellular p-ERK 1/2 expression on non-small cell lung cancer cells
A novel bronchoscopic guided non-invasive treatment for lung nodule
SYVN1-mediated ubiquitylation directs the localization of MCT4 in plasma membrane to promote the progression of lung adenocarcinoma